AR128060A1 - Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos - Google Patents
Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismosInfo
- Publication number
- AR128060A1 AR128060A1 ARP220103542A ARP220103542A AR128060A1 AR 128060 A1 AR128060 A1 AR 128060A1 AR P220103542 A ARP220103542 A AR P220103542A AR P220103542 A ARP220103542 A AR P220103542A AR 128060 A1 AR128060 A1 AR 128060A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide complexes
- antigen
- methods
- binding polypeptide
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292382P | 2021-12-21 | 2021-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128060A1 true AR128060A1 (es) | 2024-03-20 |
Family
ID=86903785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103542A AR128060A1 (es) | 2021-12-21 | 2022-12-21 | Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240059798A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452317A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503480A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240134257A (cg-RX-API-DMAC7.html) |
| CN (4) | CN118317979A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128060A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022420594A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240079A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001850A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313770A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007393A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334204A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023122659A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| WO2025249301A1 (ja) * | 2024-05-27 | 2025-12-04 | 国立大学法人東京農工大学 | 多重特異性抗体、がん増殖抑制剤、ポリヌクレオチド及び発現ベクター |
| CN121248779A (zh) * | 2024-06-25 | 2026-01-02 | 冕屹立生物技术(上海)有限公司 | 靶向人cd3分子的抗体及其应用 |
| WO2026092759A1 (en) * | 2024-11-04 | 2026-05-07 | Modex Therapeutics, Inc. | Multispecific antibodies and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9458244B2 (en) * | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
| ES2894304T3 (es) * | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| EA202091976A1 (ru) * | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| KR20210044218A (ko) * | 2018-07-11 | 2021-04-22 | 모멘타 파머슈티컬스 인코포레이티드 | CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| US12365722B2 (en) * | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| EP4578507A3 (en) * | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| US11613576B2 (en) * | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
| US20230001008A1 (en) * | 2019-08-20 | 2023-01-05 | Kumquat Biosciences Inc. | Compositions and methods for targeting cellular molecules |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN118613504A (zh) * | 2021-12-17 | 2024-09-06 | 摩德斯医疗股份有限公司 | 含有tnfsf配体的细胞外结构域的抗原结合多肽复合物 |
-
2022
- 2022-09-28 CN CN202280078695.8A patent/CN118317979A/zh active Pending
- 2022-09-28 CN CN202280078666.1A patent/CN118591388A/zh active Pending
- 2022-09-28 CN CN202280072889.7A patent/CN118251411A/zh active Pending
- 2022-12-21 MX MX2024007393A patent/MX2024007393A/es unknown
- 2022-12-21 TW TW111149263A patent/TW202334204A/zh unknown
- 2022-12-21 CN CN202280089147.5A patent/CN118715247A/zh active Pending
- 2022-12-21 AR ARP220103542A patent/AR128060A1/es unknown
- 2022-12-21 JP JP2024537849A patent/JP2025503480A/ja active Pending
- 2022-12-21 AU AU2022420594A patent/AU2022420594A1/en active Pending
- 2022-12-21 CA CA3240079A patent/CA3240079A1/en active Pending
- 2022-12-21 KR KR1020247024380A patent/KR20240134257A/ko active Pending
- 2022-12-21 IL IL313770A patent/IL313770A/en unknown
- 2022-12-21 US US18/069,529 patent/US20240059798A1/en active Pending
- 2022-12-21 WO PCT/US2022/082131 patent/WO2023122659A2/en not_active Ceased
- 2022-12-21 EP EP22912696.6A patent/EP4452317A4/en active Pending
-
2024
- 2024-06-19 CL CL2024001850A patent/CL2024001850A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134257A (ko) | 2024-09-06 |
| WO2023122659A3 (en) | 2023-08-03 |
| US20240059798A1 (en) | 2024-02-22 |
| MX2024007393A (es) | 2024-07-04 |
| CN118715247A (zh) | 2024-09-27 |
| CL2024001850A1 (es) | 2025-02-21 |
| TW202334204A (zh) | 2023-09-01 |
| CN118591388A (zh) | 2024-09-03 |
| AU2022420594A1 (en) | 2024-08-01 |
| EP4452317A2 (en) | 2024-10-30 |
| CN118317979A (zh) | 2024-07-09 |
| CA3240079A1 (en) | 2023-06-29 |
| WO2023122659A2 (en) | 2023-06-29 |
| EP4452317A4 (en) | 2025-12-10 |
| JP2025503480A (ja) | 2025-02-04 |
| CN118251411A (zh) | 2024-06-25 |
| IL313770A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| PE20210375A1 (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| BR112022001460A2 (pt) | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| CL2018003407A1 (es) | Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo. | |
| CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| ECSP22055004A (es) | Anticuerpos anti?mertk y m?todos de uso de los mismos | |
| CL2024001850A1 (es) | Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos. | |
| PE20231093A1 (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas | |
| PE20250153A1 (es) | Anticuerpos y usos de estos | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| AR128013A1 (es) | Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos | |
| CO2025006712A2 (es) | Anticuerpos |